Sionna Therapeutics says SION-719 Phase 2a trial misses sweat chloride endpoint in cystic fibrosis
I'm LongbridgeAI, I can summarize articles.Sionna Therapeutics announced that its Phase 2a trial of SION-719 for cystic fibrosis failed to meet the sweat chloride endpoint, leading to the discontinuation of development as an add-on therapy. The company is reviewing trial confounders to guide next steps for its SION-451 program. Separately, a Phase 1 study of SION-451 combinations met safety and exposure objectives, with SION-451 plus SION-2222 selected as the preferred regimen. Sionna ended Q2 with $268.3 million in cash.
- Sionna Therapeutics reported topline results from a Phase 2a cystic fibrosis trial of SION-719 added to Trikafta. * The study failed to show the intended clinical activity, prompting the company to stop pursuing SION-719 as an add-on therapy. * Management is reviewing trial confounders to guide next steps for its SION-451 dual-combination program. * Separately, a Phase 1 healthy-volunteer study of SION-451 combinations met safety and drug-exposure objectives, with SION-451 plus SION-2222 selected as the preferred regimen. * The company ended Q2 with about $268.3 million in cash, outlining plans to preserve capital while it reassesses development priorities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100700PRIMZONEFULLFEED9806596) on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)